Cargando…

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir

BACKGROUND & AIMS: Telaprevir, a hepatitis C virus NS3/4A protease inhibitor has significantly improved sustained viral response rates when given in combination with pegylated interferon alfa-2a and ribavirin, compared with current standard of care in hepatitis C virus genotype 1 infected patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Xiomara V., de Bruijne, Joep, Sullivan, James C., Kieffer, Tara L., Ho, Cynthia K. Y., Rebers, Sjoerd P., de Vries, Michel, Reesink, Hendrik W., Weegink, Christine J., Molenkamp, Richard, Schinkel, Janke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407168/ https://www.ncbi.nlm.nih.gov/pubmed/22848441 http://dx.doi.org/10.1371/journal.pone.0041191

Ejemplares similares

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
por: Haseltine, Eric L., et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Dried blood spot self-sampling at home is a feasible technique for hepatitis C RNA detection
por: Prinsenberg, Tamara, et al.
Publicado: (2020)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment
por: Sullivan, James C, et al.
Publicado: (2012)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Hepatitis E virus as a Cause of Acute Hepatitis in The Netherlands
por: Tholen, Aletta T. R., et al.
Publicado: (2016)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Erratum to: Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Pyrosequencing Bacillus anthracis
por: Wahab, Tara, et al.
Publicado: (2005)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing
por: Bansode, Vijay, et al.
Publicado: (2013)

Diversity of Pneumocystis jirovecii during Infection Revealed by Ultra-Deep Pyrosequencing
por: Alanio, Alexandre, et al.
Publicado: (2016)

High-Resolution Evolutionary Analysis of Within-Host Hepatitis C Virus Infection
por: Raghwani, Jayna, et al.
Publicado: (2019)

Development and evaluation of a four-tube real time multiplex PCR assay covering fourteen respiratory viruses, and comparison to its corresponding single target counterparts
por: Jansen, Rogier R., et al.
Publicado: (2011)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Performance of Ultra-Deep Pyrosequencing in Analysis of HIV-1 pol Gene Variation
por: Mild, Mattias, et al.
Publicado: (2011)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc
por: Rodriguez, Christophe, et al.
Publicado: (2015)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese
por: Choi, Yewon, et al.
Publicado: (2018)

PCR-Induced Transitions Are the Major Source of Error in Cleaned Ultra-Deep Pyrosequencing Data
por: Brodin, Johanna, et al.
Publicado: (2013)

Ultra-Deep Pyrosequencing (UDPS) Data Treatment to Study Amplicon HCV Minor Variants
por: Gregori, Josep, et al.
Publicado: (2013)

Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies
por: Jansen, Rogier R, et al.
Publicado: (2013)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing
por: Shaw, Richard J., et al.
Publicado: (2006)

Dynamics of HIV-1 Quasispecies during Antiviral Treatment Dissected Using Ultra-Deep Pyrosequencing
por: Hedskog, Charlotte, et al.
Publicado: (2010)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l5hpbqdc0fknmge1880sg3ddl2